Item 25.1: Baseline data

Report number of children/adolescents in the trial by prespecified age group(s)

Title and abstract	1a.1	Title and structured abstract	✓
Introduction	6.1	Background and rationale *Prevalence/incidence*	✓
	6.2	Background and rationale *Efficacy/effectiveness*	✓
	6.3	Background and rationale *Research question or aim*	✓
Methods	12a.1	Eligibility criteria *Justification for including multiple age groups*	✓
	12a.2	Eligibility criteria *Age-appropriate trial information*	✓
	13.1	Intervention and comparator *Dose/formulation*	✓
	13.2	Intervention and comparator *Intervention delivery*	✓
	14.1	Outcomes	✓
	15.1	Harms	✓
Results	25.1	Baseline data	◀
	28.1	Ancillary analyses	
Discussion	29.1	Interpretation	

Key elements for reporting this item:

• Number of children/adolescents in trial by predefined age subgroups, total, and study arm
• If the trial used developmental stage or another related factor for defining eligibility, number of children/adolescents according to this factor, total, and study arm.

Examples:

See Table 1 from Pratesi et al 2024 (Figure 5 in the E&E), for an example of a table showing material and neonatal characteristics by treatment group.

Pratesi S, Ciarcià M, Boni L, et al; PCI Trial Collaborators. Resuscitation With Placental Circulation Intact Compared With Cord Milking: A Randomized Clinical Trial. JAMA Netw Open 2024;7:e2450476. doi:10.1001/jamanetworkopen.2024.50476.

See Table 1 from Bouvier et al 2024 (Figure 6 in the E&E), for an example of a table showing the characteristics of a conventional treatment group and S100B biomonitoring group.

Bouvier D, Cantais A, Laspougeas A, et al. Serum S100B Level in the Management of Pediatric Minor Head Trauma: A Randomized Clinical Trial. JAMA Netw Open 2024;7:e242366. doi:10.1001/jamanetworkopen.2024.2366.